Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bacterial fatty acid synthesis is an essential metabolic pathway utilizing a collection of discrete enzymes to assemble fatty acids from acetyl-CoA precursors, extending them two carbons at a time via iterative reactions[1][4][5]. Key components include acetyl-CoA carboxylase, 3-ketoacyl-ACP synthases (FabB, FabF), reductases (FabG, FabI), and acyl carrier protein (ACP)[1][4][5]. This pathway differs significantly from mammalian fatty acid synthesis ("type I") and offers several points of vulnerability for antibiotic development, as the enzymes involved are structurally distinct and required for bacterial cell membrane formation[2][5]. Drug resistance can arise due to environmental fatty acid scavenging and enzymatic redundancy, complicating therapeutic interventions[2].
Enzyme inhibition (preventing successive steps in fatty acid elongation) Preventing reduction (inhibition of reductase enzymes like FabI) Blocking substrate activation (e.g., inhibiting acyl-acyl carrier protein synthetase)
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bacterial fatty acid synthase (type II) (FAS (type II); sometimes referred to as FASII).